An analysis of the placebo effect in Crohn’s disease over time
- 2 December 2009
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 31 (1) , 102-107
- https://doi.org/10.1111/j.1365-2036.2009.04125.x
Abstract
Randomized, placebo controlled trials are used to assess the efficacy of therapies for Crohn's disease. The placebo response and remission rates vary among studies. To analyse how the placebo response and remission rates in Crohn's trials have changed over time in the era of parenteral biologic therapies. A search for randomized, placebo-controlled trials of parenteral biologic therapies for active Crohn's disease was conducted using online databases. The placebo response and remission rates and study week of evaluation were recorded for each trial. The placebo response and remission rates were analysed as functions of publication date and study week of evaluation. The odds of a placebo-induced remission and response significantly increased as the week of evaluation increased. The placebo remission rate increased significantly with year of publication. Adjusted for week of evaluation, this increase in placebo remission rate over time was no longer significant. The increase in the placebo response over this time period was not statistically significant. The observed increase in placebo remission rates over time in trials of parenteral biologic therapies in Crohn's disease is explained by longer times to the primary endpoint in more recent trials.Keywords
This publication has 28 references indexed in Scilit:
- A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's DiseaseGastroenterology, 2008
- Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE TrialGastroenterology, 2007
- Onercept for Moderate-to-Severe Crohn’s Disease: A Randomized, Double-Blind, Placebo-Controlled TrialClinical Gastroenterology and Hepatology, 2006
- Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I TrialGastroenterology, 2006
- Fontolizumab, a humanised anti-interferon antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's diseaseGut, 2005
- A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn’s DiseaseGastroenterology, 2005
- Intravenous CDP870, a PEGylated Fab′ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate‐to‐severe Crohn's disease: an exploratory studyAlimentary Pharmacology & Therapeutics, 2004
- Anti–Interleukin-12 Antibody for Active Crohn's DiseaseNew England Journal of Medicine, 2004
- CDP571, a humanised monoclonal antibody to tumour necrosis factor , for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trialGut, 2004
- The Powerful Placebo Effect: Fact or Fiction?Journal of Clinical Epidemiology, 1997